Live Breaking News & Updates on Oladimeji Akinboro
Stay updated with breaking news from Oladimeji akinboro. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The analysis used data from studies of patients with advanced NSCLC and a PD-L1 tumor proportion score of 50% or higher treated in the first-line setting with either combination chemotherapy and immunotherapy, or immunotherapy alone. ....
CHICAGO — Chemoimmunotherapy and immunotherapy alone conferred comparable benefit as first-line therapy for most patients with advanced non-small cell lung cancer and high PD-L1 expression, results presented at ASCO Annual Meeting showed.Older patients appeared to derive better OS and PFS outcomes with immunotherapy alone, findings from the exploratory pooled analysis showed. ....
email article Patients with advanced non-small cell lung cancer (NSCLC) and PD-L1 scores 1%-49% who received chemoimmunotherapy regimens seemed to do better than patients treated with immunotherapy alone, according to an exploratory pooled analysis. Median overall survival (OS) among patients treated with FDA-approved immunotherapy agents was 14.5 months versus a median OS of 21.4 months for patients given chemoimmunotherapy (HR 0.68, 95% CI 0.52-0.90). Median progression-free survival (PFS) was 4.2 months versus 7.78, respectively (HR 0.68, 95% CI 0.52-0.90), reported Oladimeji Akinboro, MD, of the FDA Center for Drug Evaluation and Research in Silver Spring, Maryland, at the American Society of Clinical Oncology virtual meeting. Akinboro acknowledged that the results were limited by the study designed, which compared results across clinical trials an often-used method that is statistically challenged. These results are hypothesis generating, he stressed, ....